We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Collaboration to Develop NMR Hypersense Technology

By Biotechdaily staff writers
Posted on 17 Oct 2005
Oxford Instruments Molecular Biotools (OIMBL, Oxon, UK) has entered into three landmark collaborative agreements with Pfizer Global R&D (Sandwich, UK), Queen Mary and Westfield College, University of London (London, UK), and the University of Birmingham Institute for Cancer Studies (UK). More...
These agreements allow for the development of sophisticated and innovative applications in nuclear magnetic resonance (NMR) technology, utilizing the dramatic enhancement in the signal-to-noise ratio provided by HyperSense.

HyperSense is a novel in vitro dynamic nuclear polarization (DNP) polarizer capable of amplifying the baseline signal-to-noise ratio of NMR systems by a factor of up to 10,000 for 1D NMR spectral analysis. HyperSense is the first commercial product of its kind that enables scientists to attain an excellent level of information quality and richness, while opening up the field of practical NMR analysis to totally new areas of research. It is a modular instrument that will attach to any traditional NMR system, to deliver polarization-enhanced samples using a solid-state dynamic nuclear polarization (DNP) technique recently licensed from GE Healthcare (Waukesha, WI, USA).

The collaborators, representing some of the major NMR groups across academia and industry in the United Kingdom, will evaluate different aspects of the use of the enhanced levels of signal-to-noise ratio provided by HyperSense, in applications across life science research, pharmaceuticals, and chemistry.

At the biomolecular NMR spectroscopy laboratory at the University of Birmingham, Prof. Michael Overduin and Dr. Ulrich Günther of the CRC Institute for Cancer Studies (Birmingham, UK) will use HyperSense to conduct additional studies to identify biologic markers for different types of cancer and to develop new methods for determining the kinetics and dynamics of protein-ligand interactions.

The diversity of NMR research applications directly reflects the flexibility of applications for HyperSense. By providing the information richness of NMR and enhancing the signal-to-noise ratio by up to 10,000 fold, this technique avoids time-consuming and labor-intensive enrichment processes that were once a requisite.


Related Links:
Oxford Instruments Molecular Biotools

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Clinical Chemistry Analyzer
Envoy 500+
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.